Overektomili sıçanlarda alendronatın böbrek dokusu üzerindeki etkileri

Alendronat kemik rezorpsiyonunun selektif inhibitörü olan bir aminobifosfonat olup özellikle postmenopozal dönemde görülen osteoporozun tedavisinde kullanılmaktadır. Postmenopozda ortaya çıkan değişikliklerin yaşam kalitesini etkilediği bilinmektedir. Bu çalışmada overektomili sıçanlar üzerinde alendronat tedavisinin zamana bağlı olarak böbrekteki oksidan durum üzerinde etkisi incelenmiştir. Overektomi yapılan sıçanlara 2, 4 ve 8 hafta alendronat (0.3 mg/kg) intravenöz uygulanmıştır. Serumda ürik asit ve kreatinin düzeyleri, böbrek dokusunda malondialdehid (MDA) ve glutatyon (GSH) düzeyi, katalaz (CAT), süperoksid dismutaz (SOD) ve miyeloperoksidaz (MPO) aktivitesine bakılmıştır. Overektomili sıçanlarda serum kreatinin ve ürik asit düzeylerinin yükseldiği, alendronat tedavisi ile zaman bağlı olarak azaldığı görülmüştür. Böbrek MDA düzeyleri ve MPO aktivitesinin hem overektomi grubunda hem de alendronat tedavisi alan gruplarda yükseldiği görülmüştür. Buna karşın overektomili grupta böbrek GSH, SOD ve CAT düzeylerinin azaldığı, alendronat tedavisi ile zamana bağlı olarak arttığı gözlenmiştir. Sonuç olarak kemik rezorbsiyonun görüldüğü overektomide böbrek dokusunda bazı oksidatif değişiklikler meydana geldi ve alendronat tedavisinin zamana bağlı olarak antioksidan kapasiteyi arttırdığı bu çalışmada gösterilmiştir.

Effects of alendronate on kidney tissue of ovariectomized rats

Alendronate is an aminophosphanate, selective inhibitory of bone resorbtion, used for treatment of osteoporosis in postmenopause. It is known that changes occurring in postmenopausal period effect the quality of life. In this study, effect of the alendronate treatment time on renal oxidative status was investigated in ovariectomized rats. Alendronate was intravenous administered at 0.3 mg/kg dosage on weeks 2, 4 and 8. Serum creatinine and uric acid levels and kidney malondialdehyde (MDA), glutathione (GSH), catalase (CAT), superoxide dismutase (SOD) and myeloperoxidase (MPO) level and activities were measured. Serum creatinine and uric acid levels increased in depending on the time of alendronate treatment on ovariectomized rats. Kidney MDA level and MPO activity increased in both ovariectomized and alendronate groups. Kidney GSH level and SOD and CAT activities decreased in the ovariectomized rats and these levels increased in depending on time of alendronate treatment. As a result, some oxidative changes occurred in the kidney tissue of ovariectomized rats with bone resorption and alendronate treatment increased the antioxidant capacity in depending on the time.

PDF

___

1. Russell RG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int, 9 (2): 66-80, 1999.
2. Bağış T, Bağış S, Gökçel A, Kıllıcadağ E, Tarım E, Saygılı Yılmaz E: Postmenopozal osteoporoz tedavisinde hormon replasman tedavisi ve alendronate: kombine edelim mi? T Klin Jinekol Obst, 12 (6): 504-508, 2002.
3. Giger EV, Castagner B, Leroux JC: Biomedical applications of bisphosphonates. J Control Release, 167 (2): 175-88, 2013.
4. Köşüş A, Köşüş N, Çapar M: Comparision of single agent and combination therapy of alendronate and tibolone in postmenopausal osteoporosis. Turkiye Klinikleri J Gynecol Obst, 15 (2): 81-86, 2005.
5. Rennert G: Bisphosphonates: beyond prevention of bone metastases. J Natl Cancer Inst, 103 (23): 1728-1729, 2011.
6. Karabulut AB, Gül M, Karabulut E, Kiran TR, Ocak SG, Otlu O: Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid. Transplant Proc, 42 (9): 3820-3822, 2010.
7. Zinnuroglu M, Dincel AS, Kosova F, Sepici V, Karatas GK: Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis. Rheumatol Int, 32 (4): 875-880, 2012.
8. Bonnes RW, Taussky HH: The colorimetric determination of creatinine by the Jaffes reaction. J Biol Chem, 158, 581-589, 1945.
9. Beuge JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol, 52, 302-311, 1978.
10. Beutler E: A Manual of Biochemical Methods. Glutathione in red blood cell metabolism. 3rd ed., 112-114, Grune and Stratton, New York, 1975.
11. Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow C: Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods, 24 (4): 285-295, 1990.
12. Aebi H: Catalase in vitro. Methods Enzymol, 105, 121-126, 1984.
13. Mylroie AA, Collins H, Umbles C, Kyle J: Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol, 82, 512-520, 1986.
14. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem, 72, 248-254, 1976.
15. Gertz BJ, Holland SD, Kline WF: Studies of the oral biovailability of Alendronat. Clin Pharmacol Ther, 58 (3): 288-298, 1995.
16. Miller PD: The kidney and bisphosphonates. Bone, 49 (1): 77-81, 2011.
17. Sener A, Altundal H, Goker B, Yurtsever E: Alendronatın diş çekimi sonrası ratlarda plazma biyokimyasal parametrelerine ve oksidatif strese etkisi. GÜ Diş Hek Fak Derg, 26 (3): 147-153, 2009.
18. Kovac D, Lindic J, Kandus A, Bren AF: Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation, 70 (10): 1542-1543, 2000.
19. Shahbazian H, Mowla K, Shahbazian HB, Peydayesh B, Ehsanpour A: Efficacy and safety of alendornate in the prevention of bone loss in renal transplant recipients. Indian Journal of Nephrology, 17 (2): 61-66, 2007.
20. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T: Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemi. Lancet, 354 (9179): 650, 1999.
21. Hak AE, Choi HK: Menopause, postmenopausal hormone use and serum uric acid levels in US women-the Third National Health and Nutrition Examination Survey. Arthritis Res Ther, 10 (5): R116, 2008.
22. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR: Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res, 22 (4): 503-508, 2007.
23. Spector A: Review: Oxidative stress and disease. J Ocul Pharmacol Ther, 16 (2): 193-201, 2000.
24. Sanchez-Rodriguez MA, Zacarias-Flores M, Arronte-Rosales A, Correa-Munoz E, Mendoza-Nunez VM: Menopause as risk factor for oxidative stress. Menopause, 19 (3): 361-7, 2012.
25. Naito Y, Lee MC, Kato Y, Nagai R, Yonei Y: Oxidative stress markers. Anti-Aging Medicine, 7 (5): 36-44, 2010.
26. Nagy P, Kettle AJ, Winterbourn CC: Neutrophil-mediated oxidation of enkephalins via myeloperoxidase-dependent addition of superoxide. Free Radic Biol Med, 49 (5): 792-799, 2010.
27. Ross D: Glutathione free radicals and chemotherapeutic agents. Pharmac Ther, 37 (2): 231-249, 1988.
28. Ha BJ: Oxidative stress in ovariectomy menopause and role of chondroitin sulfate. Arch Pharm Res, 27 (8): 867-872, 2004.
29. Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z: Role of antioxidant systems, lipid peroxidation, and nitric oxide in post-menopausal osteoporosis. Mol Cell Biochem, 295 (1-2): 45-52, 2007.
30. Gomez-Zubeldia MA, Hernandez R, Viguera J, Arbues JJ, Aparicio A, Millan JC: Effect of bilateral ovariectomy and ovarian steroid hormones on the antioxidant systems and plasma malondialdehyde levels in Wistar rats. Endocr Res, 26 (1): 97-107, 2000.
31. Muthusami S, Ramachandran I, Muthusamy B, Vasudevan G, Prabhu V, Subramaniam V, Jagadeesan A, Narasimhan S: Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta, 360 (1-2): 81-86, 2005.
32. Işeri SO, Sener G, Yüksel M, Contuk G, Cetinel S, Gedik N, Yegen BC: Ghrelin against alendronate-induced gastric damage in rats. J Endocrinol, 187 (3): 399-406, 2005.
33. Yalın S, Çömelekoğlu Ü, Bağış S, Berköz M, Eroğlu P: Effects of alendronate and risedronate therapy on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats. Turk J Med Sci, 40 (4): 613-618, 2010.
34. Konyalioglu S, Durmaz G, Yalcin A: The potential antioxidant effect of raloxifene treatment: A study on heart, liver and brain cortex of ovariectomized female rats. Cell Biochem Funct, 25 (3): 259-266, 2007.
35. Benghuzzi H, Mohamed A, Aneja A, Cameron JA, Tucci M: The effects of sustained delivery of alendronate on the kidney in ovariectomized female rats. Biomed Sci Instrum, 48, 35-42, 2012.